390 related articles for article (PubMed ID: 22056257)
1. Omalizumab for the treatment of atopic dermatitis.
Fernández-Antón Martínez MC; Leis-Dosil V; Alfageme-Roldán F; Paravisini A; Sánchez-Ramón S; Suárez Fernández R
Actas Dermosifiliogr; 2012 Sep; 103(7):624-8. PubMed ID: 22056257
[TBL] [Abstract][Full Text] [Related]
2. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis.
Kim DH; Park KY; Kim BJ; Kim MN; Mun SK
Clin Exp Dermatol; 2013 Jul; 38(5):496-500. PubMed ID: 23083013
[TBL] [Abstract][Full Text] [Related]
3. Anti-immunoglobulin e in the treatment of refractory atopic dermatitis.
Amrol D
South Med J; 2010 Jun; 103(6):554-8. PubMed ID: 20710140
[TBL] [Abstract][Full Text] [Related]
4. [Dermatological implications of omalizumab, an anti-IgE antibody].
Di Lucca-Chrisment J
Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab treatment in severe adult atopic dermatitis.
Thaiwat S; Sangasapaviliya A
Asian Pac J Allergy Immunol; 2011 Dec; 29(4):357-60. PubMed ID: 22299316
[TBL] [Abstract][Full Text] [Related]
6. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.
Sánchez-Ramón S; Eguíluz-Gracia I; Rodríguez-Mazariego ME; Paravisini A; Zubeldia-Ortuño JM; Gil-Herrera J; Fernández-Cruz E; Suárez-Fernández R
J Investig Allergol Clin Immunol; 2013; 23(3):190-6. PubMed ID: 23967758
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases.
Toledo F; Silvestre JF; Muñoz C
J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1325-7. PubMed ID: 22050044
[No Abstract] [Full Text] [Related]
8. Omalizumab beyond asthma.
Sanchez J; Ramirez R; Diez S; Sus S; Echenique A; Olivares M; Cardona R
Allergol Immunopathol (Madr); 2012; 40(5):306-15. PubMed ID: 22264640
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema.
Ramírez del Pozo ME; Contreras Contreras E; López Tiro J; Gómez Vera J
J Investig Allergol Clin Immunol; 2011; 21(5):416-7. PubMed ID: 21905512
[No Abstract] [Full Text] [Related]
10. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy.
Velling P; Skowasch D; Pabst S; Jansen E; Tuleta I; Grohé C
Eur J Med Res; 2011 Sep; 16(9):407-10. PubMed ID: 22024441
[TBL] [Abstract][Full Text] [Related]
11. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI.
Forman SB; Garrett AB
Cutis; 2007 Jul; 80(1):38-40. PubMed ID: 17725062
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.
Scheinfeld N
Dermatol Online J; 2005 Mar; 11(1):2. PubMed ID: 15748543
[TBL] [Abstract][Full Text] [Related]
13. [Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit].
Schmitt J; Schäkel K
Hautarzt; 2007 Feb; 58(2):128, 130-2. PubMed ID: 17237929
[TBL] [Abstract][Full Text] [Related]
14. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis.
Incorvaia C; Pravettoni C; Mauro M; Yacoub MR; Tarantini F; Riario-Sforza GG
Monaldi Arch Chest Dis; 2008 Jun; 69(2):78-80. PubMed ID: 18837422
[TBL] [Abstract][Full Text] [Related]
16. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines.
Hotze M; Baurecht H; Rodríguez E; Chapman-Rothe N; Ollert M; Fölster-Holst R; Adamski J; Illig T; Ring J; Weidinger S
Allergy; 2014 Jan; 69(1):132-5. PubMed ID: 24111531
[TBL] [Abstract][Full Text] [Related]
17. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.
Iyengar SR; Hoyte EG; Loza A; Bonaccorso S; Chiang D; Umetsu DT; Nadeau KC
Int Arch Allergy Immunol; 2013; 162(1):89-93. PubMed ID: 23816920
[TBL] [Abstract][Full Text] [Related]
18. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
20. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
